Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (115)
ARTG (99)
Prescription medicine registration (52)
Australian Public Assessment Report (AusPAR) (31)
Designation or determination (31)
Prescription medicine evaluation (9)
Prescription medicine decision summary (2)

Date

2024 (25)
2023 (33)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (12)
2013 (16)
2012 (6)
2011 (4)
2009 (10)
2008 (6)
2007 (6)
2006 (10)
2005 (1)
2003 (1)
2002 (7)
2000 (1)
1998 (1)
1997 (5)
1996 (1)
1993 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

339 result(s) found, displaying 31 to 40

TBC Merck Sharp & Dohme (Australia) Pty Ltd

Jan-2024

Prescription medicine evaluation

Active ingredient: Pneumococcal purified capsular polysaccharides.
TUKYSA (Merck Sharp & Dohme (Australia) Pty Ltd)

17 November 2023

Prescription medicine registration

Active ingredients: tucatinib.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd

Nov-2023

Prescription medicine evaluation

Active ingredient: pembrolizumab.
SILUMBRA suvorexant 15mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

10 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SILUMBRA suvorexant 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

10 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MSD-ERTUGLIFLOZIN-METFORMIN 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MSD-ERTUGLIFLOZIN-METFORMIN 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MSD-ERTUGLIFLOZIN-METFORMIN 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MSD-ERTUGLIFLOZIN-METFORMIN 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MSD-ERTUGLIFLOZIN-SITAGLIPTIN 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 October 2023

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.